The FDA’s approval of the first therapy to treat Alzheimer’s Disease in over twenty years brought attention to a not-yet-convened debate of U.S. health care costs and spending, innovation, and return-on-the-investment (as well as “for whom” do the returns accrue). In my latest post for Medecision, I explore different angles on the Aduhelm and Alzheimer’s… Read More »
More evidence has been uncovered that Alzheimer’s disease may actually be a third form of diabetes, according to researchers from Northwestern University. Insulin and insulin receptors in your brain are crucial for learning and memory, and it’s known that these components are lower in people with Alzheimer’s disease. In your brain, insulin binds to an… Read More »
Researchers have shown that clearance of the substance amyloid-beta that forms plaques is impaired in individuals with Alzheimer’s. A group of 12 individuals with early Alzheimer’s were compared to 12 cognitively normal individuals of the same age. Amyloid-beta was produced at the same average rate by both groups, but in the Alzheimer’s group there was… Read More »